The Gabrail Cancer and Research Center has received FDA authorization to proceed with an investigator-initiated trial combining the BCMA-directed T-cell engager elranatamab with Starton Therapeutics’ STAR-LLD controlled low-dose lenalidomide in relapsed or refractory multiple myeloma. The study is designed to test whether sustained low-dose immunomodulation can improve the durability of bispecific-antibody activity while reducing the hematologic toxicity associated with adding conventional oral lenalidomide. Enrollment is expected to begin during the fourth quarter of 2026 after remaining site and regulatory requirements are completed.
The combination is scientifically interesting because each component represents an established therapeutic idea being used in a new way. Elranatamab is a BCMA x CD3 bispecific antibody that redirects the patient’s own T cells toward multiple myeloma cells. Lenalidomide is an immunomodulatory drug with a long history in myeloma treatment. Starton’s experimental formulation attempts to deliver much lower, steadier exposure rather than the peaks associated with ordinary oral tablets. The hypothesis is that enough lenalidomide may remain available to improve T-cell fitness and the tumor immune environment without adding so much bone-marrow suppression that patients cannot tolerate the combination.
Why do responses to BCMA bispecific antibodies eventually stop working in some patients?
Bispecific T-cell engagers have transformed treatment for heavily pretreated multiple myeloma by physically connecting T cells to cancer cells. One portion of the antibody binds BCMA on plasma-cell malignancies, while the other engages CD3 on T cells, creating direct immune contact capable of killing the tumor.
The approach can produce deep responses even after several earlier lines of therapy, but many patients eventually relapse. Resistance can occur through several mechanisms, including changes in tumor antigen expression, immunosuppressive features of the bone-marrow environment and deterioration in the functional fitness of repeatedly stimulated T cells.
T cells exposed continuously to tumor antigen can become exhausted, showing lower proliferative capacity and impaired killing function. The clinical challenge is therefore not simply getting T cells to recognize myeloma once; developers want those T cells to remain functional long enough to maintain disease control.
The Gabrail study is built around the idea that immunomodulatory therapy might improve that cellular environment and extend the useful life of the bispecific response.
Why not simply combine standard lenalidomide tablets with elranatamab?
Conventional lenalidomide has substantial immunomodulatory activity, but it can also suppress blood-cell production. Elranatamab itself can contribute to infections and cytopenias, creating concern that combining a full oral lenalidomide regimen with a T-cell engager could produce excessive hematologic toxicity.
The Business Wire announcement identifies this as a central reason for testing STAR-LLD. Standard IMiD combinations can lead to dose reductions, interruptions or discontinuation when low neutrophils, low platelets or infections become difficult to manage.
A theoretically powerful combination has limited value if patients cannot remain on it long enough for the biology to work.
STAR-LLD is designed to produce sustained low lenalidomide exposure while avoiding high peak concentrations associated with conventional oral dosing. The trial will explore whether that pharmacokinetic profile preserves enough immunomodulatory effect to support T cells while reducing the toxicity burden.
That remains a hypothesis. The formulation has not yet proved that it can achieve a better therapeutic window with elranatamab in myeloma patients.
What will the new investigator-initiated trial actually measure?
The study will begin as a dose-finding and safety investigation rather than a definitive Phase 3 comparison. Investigators will evaluate tolerability of STAR-LLD alongside elranatamab and examine preliminary evidence of efficacy, including whether responses are sufficiently durable to justify a larger development program.
Blood counts and infection rates are likely to be particularly important because lowering hematologic toxicity is one of the principal reasons for using the controlled-delivery formulation.
Researchers will also need to establish what dose of STAR-LLD produces useful biological exposure. Too little lenalidomide could fail to meaningfully affect T-cell function, while too much could recreate the toxicity problem the formulation is supposed to solve.
The trial’s community-oncology setting is also notable. Gabrail Cancer Center argues that many U.S. myeloma patients receive care outside large academic institutions and that studying the regimen in such an environment can provide evidence closer to routine clinical practice.
What is elranatamab and where does it already fit in multiple myeloma?
Elranatamab is Pfizer’s BCMA-directed bispecific antibody, marketed as Elrexfio in approved settings. It binds BCMA on malignant plasma cells and CD3 on T cells, activating immune killing.
BCMA has become one of the dominant targets in advanced multiple myeloma, supporting both CAR-T cell therapies and bispecific antibodies.
CAR-T treatment requires collection and manufacturing of a patient’s cells and is generally concentrated at specialist centers. Bispecific antibodies are off-the-shelf medicines, which can make them operationally easier to use in a broader range of oncology practices once patients have completed required monitoring and step-up dosing procedures.
That accessibility is one reason improving bispecific durability could have significant clinical consequences. A regimen that keeps an off-the-shelf T-cell engager working longer could delay the need for another complex treatment transition.
How could lenalidomide improve T-cell engager activity?
Lenalidomide has multiple immunological effects beyond directly inhibiting myeloma cells. It can alter cytokine signaling, influence T-cell activation and change interactions between malignant plasma cells and the surrounding bone-marrow microenvironment.
This makes it biologically attractive as a partner for T-cell-directed therapy.
The challenge is separating the immunological benefit from systemic toxicity.
Starton’s strategy essentially treats concentration over time as part of the drug’s mechanism. Instead of giving enough oral drug to create repeated high peaks, controlled delivery attempts to hold plasma exposure within a lower range for longer periods.
If that approach maintains useful immune modulation, it could demonstrate that an old active ingredient can behave differently when its pharmacokinetics are redesigned.
That idea has implications beyond this particular trial because many highly active cancer combinations fail not because the biology is wrong but because overlapping toxicity prevents clinicians from delivering adequate doses.
What does FDA authorization to proceed actually mean?
The FDA has allowed the investigator’s IND to proceed without placing the study on clinical hold. That means the agency reviewed the submitted safety and protocol information sufficiently to permit human testing.
It does not mean the FDA has approved STAR-LLD, endorsed the combination or concluded that it is safe or effective.
The Business Wire release states this distinction explicitly. STAR-LLD and its use with elranatamab remain investigational, and the safety and effectiveness of the combination have not been established.
This is important because “FDA clears trial” headlines can easily be misread as product approval.
The meaningful milestone is that investigators can now begin generating the human evidence needed to answer the combination question.
Why is infection risk such an important issue in advanced multiple myeloma?
Multiple myeloma itself interferes with normal antibody-producing plasma cells, weakening immune defense. Patients are frequently older and have already received several therapies that further suppress immune function.
BCMA-directed treatments can deepen this vulnerability because BCMA is also expressed on normal plasma cells. Profound reductions in immunoglobulin levels can leave patients more susceptible to bacterial and viral infections.
Lenalidomide can add further bone-marrow suppression, particularly neutropenia.
A combination that produces extraordinary tumor responses but substantially increases serious infections may not have a favorable overall benefit-risk profile.
This is why STAR-LLD’s promise depends not only on showing that response rates remain high but on demonstrating that lower peak drug exposure genuinely makes the combination easier to sustain.
Could controlled delivery extend the commercial life of established cancer drugs?
Potentially.
Pharmaceutical innovation does not always require a completely new molecule. Changing formulation, route or exposure pattern can create clinically meaningful differences when the original drug’s efficacy is constrained by pharmacokinetics or toxicity.
Lenalidomide is a particularly interesting candidate because its biological activity is well understood and it is already embedded deeply in myeloma treatment.
A controlled low-dose formulation would need to show more than convenience. Its value comes from potentially making combinations possible that conventional dosing cannot tolerate.
If STAR-LLD eventually demonstrates better durability with fewer cytopenias and infections, the technology could also be explored alongside other T-cell engagers or immune therapies.
If the toxicity difference is small, physicians may prefer familiar oral regimens whose dosing can already be adjusted individually.
Why conduct this trial in a community oncology setting?
Much cutting-edge cellular and immunotherapy research begins at academic centers with highly specialized infrastructure. That makes sense scientifically but can create questions about whether a regimen remains manageable in ordinary oncology practices.
The Gabrail Cancer Center is part of PhaseWell Research and treats patients in a community setting. The trial therefore provides an opportunity to understand whether a bispecific-plus-immunomodulator combination can be delivered outside major tertiary centers.
This matters if the long-term commercial ambition is broad accessibility.
A therapy whose toxicity requires constant academic-center hospitalization will have a much narrower real-world footprint than one that can be managed by trained community oncologists.
However, investigators should not overstate the representativeness of one specialist community center. Expansion to multiple settings would still be needed if the regimen progresses.
What should multiple myeloma specialists watch once enrollment begins?
The first issue is hematologic toxicity. The entire formulation thesis will be challenged quickly if substantial neutropenia, thrombocytopenia or treatment interruption remains common.
The second is infection. Severe infections need to be compared carefully with what clinicians expect from elranatamab alone in similar patients.
The third is response durability. A modest response-rate increase may be less important than maintaining deep responses substantially longer.
Finally, investigators need pharmacokinetic data showing that the controlled formulation actually delivers the sustained low exposure it was designed to create.
The program is early, but the question is sensible. T-cell engagers have already shown that they can produce powerful responses. The next challenge is preventing those responses from fading without adding so much additional toxicity that patients lose the benefit. STAR-LLD is essentially trying to use drug delivery to thread that needle.
